Claims for Patent: 11,052,196

Summary for Patent: 11,052,196

Title:	Method of injecting octreotide acetate into the body
Abstract:	A method of providing and/or injecting octreotide acetate to a subject in need thereof includes storing the octreotide acetate in a cartridge of a multi-use multi-dose injector provided with a variable dose setter and actuator. The injector includes a needle configured for subcutaneous administration of the octreotide acetate, the octreotide acetate having a concentration of 2,500 μg/mL. The method further includes providing, on the injector, a plurality of indicia only at prescribed doses of 50 μg, 100 μg, 150 μg and 200 μg settable via the dose setter without indicia between said prescribed doses; and permitting setting of a dose of the octreotide acetate by rotation of the variable dose setter, wherein the injector is configured to provide at least one audible feedback during the rotation.
Inventor(s):	Satyashodhan Babasaheb Patil, Sudeep Kumar Agrawal
Assignee:	Sun Pharmaceutical Industries Ltd
Application Number:	US17/087,670
Patent Claims:	1. A method of treating one or more of acromegaly, carcinoid tumors or vasoactive intestinal peptide tumors by providing and/or injecting octreotide acetate to a subject in need thereof, comprising: storing the octreotide acetate in a cartridge of a multi-use multi-dose injector provided with a variable dose setter and an actuator, the injector comprising a needle configured for subcutaneous administration of the octreotide acetate, the octreotide acetate having a concentration of 2,500 μg/mL; providing, on the injector, a plurality of indicia only at prescribed doses of 50 μg, 100 μg, 150 μg and 200 μg settable via the dose setter without indicia between said prescribed doses; and permitting setting of a dose of the octreotide acetate by rotation of the variable dose setter, wherein the injector is configured to provide at least one audible feedback during the rotation. 2. The method of claim 1, wherein the actuator is operable to discharge the octreotide acetate from the cartridge through the needle, and wherein a visible surface of the actuator has a first chromatic value, at least a portion of the dose setter surrounding the actuator has a second chromatic value differing from the first chromatic value, and at least a portion of a body of the injector has a third chromatic value differing from the first chromatic value and the second chromatic value. 3. The method of claim 1, wherein the injector is configured to be primed prior to delivery of a first dose, wherein the priming is carried out by setting the dose setter to a non-zero value and operating the actuator. 4. The method of claim 3, wherein the non-zero value is 100 μg. 5. The method of claim 1, wherein the needle comprises a 31 gauge needle having a length of approximately 5 mm and is configured to be threadably connected to another component of the injector before use, and disconnected from the another component and disposed of after use. 6. The method of claim 5, further comprising arranging the injector such that the needle is insertable into an injection site at 90° relative to the injection site. 7. The method of claim 1, further comprising providing a prescribed dose in excess of 200 μg by two or more injections in a session. 8. The method of claim 7, wherein providing the prescribed dose comprises: turning the dose setter to 200 μg; delivering, to a first injection site, a first injection of 200 μg; turning the dose setter to one of the plurality of indicia; and delivering, to a second injection site differing from the first injection site, a second injection. 9. The method of claim 1, wherein the injector is disposable. 10. The method of claim 1, wherein the indicia are provided so as to correspond to dose volumes of 20 μL, 40 μL, 60 μL and 80 μL. 11. The method of claim 1, wherein the injector is configured to deliver a prescribed dose subcutaneously to one or more injection sites of an abdomen, a thigh, or an upper arm of the subject in need thereof. 12. The method of claim 1, further comprising providing at least one audible feedback during delivering of the dose.